STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma

Ling Geng, Eric T. Shinohara, Dong Kim, Jiahuai Tan, Kate Osusky, Yu Shyr, Dennis E. Hallahan

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Purpose: Glioblastoma multiforme (GBM) is a devastating brain neoplasm that is essentially incurable. Although radiation therapy prolongs survival, GBMs progress within areas of irradiation. Recent studies in invertebrates have shown that STI571 (Gleevec; Novartis, East Hanover, NJ) enhances the cytotoxicity of ionizing radiation. In the present study, the effectiveness of STI571 in combination with radiation was studied in mouse models of GBM. Methods and Materials: Murine GL261 and human D54 GBM cell lines formed tumors in brains and hind limbs of C57BL6 and nude mice, respectively. GL261 and D54 cells were treated with 5 μmol/L of STI571 for 1 h and/or irradiated with 3 Gy. Protein was analyzed by Western immunoblots probed with antibodies to caspase 3, cleaved caspase 3, phospho-Akt, Akt, and platelet-derived growth factor receptor (PDGFR) α and β. Tumor volumes were assessed in mice bearing GL261 or D54 tumors treated with 21 Gy administered in seven fractionated doses. Histologic sections from STI571-treated mice were stained with phospho-Akt and phospho-PDGFR β antibodies. Kaplan-Meier survival curves were used to study the response of mice bearing intracranial implants of GL261. Results: STI571 penetrated the blood-brain barrier, which resulted in a reduction in phospho-PDGFR in GBM. STI571-induced apoptosis in GBM was significantly enhanced by irradiation. STI571 combined with irradiation induced caspase 3 cleavage in GBM cells. Glioblastoma multiforme response to therapy correlated with an increase in tumor growth delay and survival when STI571 was administered in conjunction with daily irradiation. Conclusion: These findings suggest that STI571 has the potential to augment radiotherapy and thereby improve median survival.

Original languageEnglish (US)
Pages (from-to)263-271
Number of pages9
JournalInternational Journal of Radiation Oncology Biology Physics
Volume64
Issue number1
DOIs
StatePublished - Jan 1 2006

Fingerprint

Glioblastoma
mice
tumors
platelets
Survival
Growth
irradiation
Neoplasms
antibodies
Platelet-Derived Growth Factor Receptors
brain
radiation therapy
Caspase 3
invertebrates
blood-brain barrier
neoplasms
apoptosis
limbs
cells
cultured cells

Keywords

  • Brain neoplasms
  • Gleevec
  • Glioblastoma multiforme
  • Radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma. / Geng, Ling; Shinohara, Eric T.; Kim, Dong; Tan, Jiahuai; Osusky, Kate; Shyr, Yu; Hallahan, Dennis E.

In: International Journal of Radiation Oncology Biology Physics, Vol. 64, No. 1, 01.01.2006, p. 263-271.

Research output: Contribution to journalArticle

Geng, Ling ; Shinohara, Eric T. ; Kim, Dong ; Tan, Jiahuai ; Osusky, Kate ; Shyr, Yu ; Hallahan, Dennis E. / STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma. In: International Journal of Radiation Oncology Biology Physics. 2006 ; Vol. 64, No. 1. pp. 263-271.
@article{96dc8f1b2a7544f4a57d1f39579f10dd,
title = "STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma",
abstract = "Purpose: Glioblastoma multiforme (GBM) is a devastating brain neoplasm that is essentially incurable. Although radiation therapy prolongs survival, GBMs progress within areas of irradiation. Recent studies in invertebrates have shown that STI571 (Gleevec; Novartis, East Hanover, NJ) enhances the cytotoxicity of ionizing radiation. In the present study, the effectiveness of STI571 in combination with radiation was studied in mouse models of GBM. Methods and Materials: Murine GL261 and human D54 GBM cell lines formed tumors in brains and hind limbs of C57BL6 and nude mice, respectively. GL261 and D54 cells were treated with 5 μmol/L of STI571 for 1 h and/or irradiated with 3 Gy. Protein was analyzed by Western immunoblots probed with antibodies to caspase 3, cleaved caspase 3, phospho-Akt, Akt, and platelet-derived growth factor receptor (PDGFR) α and β. Tumor volumes were assessed in mice bearing GL261 or D54 tumors treated with 21 Gy administered in seven fractionated doses. Histologic sections from STI571-treated mice were stained with phospho-Akt and phospho-PDGFR β antibodies. Kaplan-Meier survival curves were used to study the response of mice bearing intracranial implants of GL261. Results: STI571 penetrated the blood-brain barrier, which resulted in a reduction in phospho-PDGFR in GBM. STI571-induced apoptosis in GBM was significantly enhanced by irradiation. STI571 combined with irradiation induced caspase 3 cleavage in GBM cells. Glioblastoma multiforme response to therapy correlated with an increase in tumor growth delay and survival when STI571 was administered in conjunction with daily irradiation. Conclusion: These findings suggest that STI571 has the potential to augment radiotherapy and thereby improve median survival.",
keywords = "Brain neoplasms, Gleevec, Glioblastoma multiforme, Radiation therapy",
author = "Ling Geng and Shinohara, {Eric T.} and Dong Kim and Jiahuai Tan and Kate Osusky and Yu Shyr and Hallahan, {Dennis E.}",
year = "2006",
month = "1",
day = "1",
doi = "10.1016/j.ijrobp.2005.08.025",
language = "English (US)",
volume = "64",
pages = "263--271",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma

AU - Geng, Ling

AU - Shinohara, Eric T.

AU - Kim, Dong

AU - Tan, Jiahuai

AU - Osusky, Kate

AU - Shyr, Yu

AU - Hallahan, Dennis E.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Purpose: Glioblastoma multiforme (GBM) is a devastating brain neoplasm that is essentially incurable. Although radiation therapy prolongs survival, GBMs progress within areas of irradiation. Recent studies in invertebrates have shown that STI571 (Gleevec; Novartis, East Hanover, NJ) enhances the cytotoxicity of ionizing radiation. In the present study, the effectiveness of STI571 in combination with radiation was studied in mouse models of GBM. Methods and Materials: Murine GL261 and human D54 GBM cell lines formed tumors in brains and hind limbs of C57BL6 and nude mice, respectively. GL261 and D54 cells were treated with 5 μmol/L of STI571 for 1 h and/or irradiated with 3 Gy. Protein was analyzed by Western immunoblots probed with antibodies to caspase 3, cleaved caspase 3, phospho-Akt, Akt, and platelet-derived growth factor receptor (PDGFR) α and β. Tumor volumes were assessed in mice bearing GL261 or D54 tumors treated with 21 Gy administered in seven fractionated doses. Histologic sections from STI571-treated mice were stained with phospho-Akt and phospho-PDGFR β antibodies. Kaplan-Meier survival curves were used to study the response of mice bearing intracranial implants of GL261. Results: STI571 penetrated the blood-brain barrier, which resulted in a reduction in phospho-PDGFR in GBM. STI571-induced apoptosis in GBM was significantly enhanced by irradiation. STI571 combined with irradiation induced caspase 3 cleavage in GBM cells. Glioblastoma multiforme response to therapy correlated with an increase in tumor growth delay and survival when STI571 was administered in conjunction with daily irradiation. Conclusion: These findings suggest that STI571 has the potential to augment radiotherapy and thereby improve median survival.

AB - Purpose: Glioblastoma multiforme (GBM) is a devastating brain neoplasm that is essentially incurable. Although radiation therapy prolongs survival, GBMs progress within areas of irradiation. Recent studies in invertebrates have shown that STI571 (Gleevec; Novartis, East Hanover, NJ) enhances the cytotoxicity of ionizing radiation. In the present study, the effectiveness of STI571 in combination with radiation was studied in mouse models of GBM. Methods and Materials: Murine GL261 and human D54 GBM cell lines formed tumors in brains and hind limbs of C57BL6 and nude mice, respectively. GL261 and D54 cells were treated with 5 μmol/L of STI571 for 1 h and/or irradiated with 3 Gy. Protein was analyzed by Western immunoblots probed with antibodies to caspase 3, cleaved caspase 3, phospho-Akt, Akt, and platelet-derived growth factor receptor (PDGFR) α and β. Tumor volumes were assessed in mice bearing GL261 or D54 tumors treated with 21 Gy administered in seven fractionated doses. Histologic sections from STI571-treated mice were stained with phospho-Akt and phospho-PDGFR β antibodies. Kaplan-Meier survival curves were used to study the response of mice bearing intracranial implants of GL261. Results: STI571 penetrated the blood-brain barrier, which resulted in a reduction in phospho-PDGFR in GBM. STI571-induced apoptosis in GBM was significantly enhanced by irradiation. STI571 combined with irradiation induced caspase 3 cleavage in GBM cells. Glioblastoma multiforme response to therapy correlated with an increase in tumor growth delay and survival when STI571 was administered in conjunction with daily irradiation. Conclusion: These findings suggest that STI571 has the potential to augment radiotherapy and thereby improve median survival.

KW - Brain neoplasms

KW - Gleevec

KW - Glioblastoma multiforme

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=29244438974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29244438974&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2005.08.025

DO - 10.1016/j.ijrobp.2005.08.025

M3 - Article

C2 - 16274936

AN - SCOPUS:29244438974

VL - 64

SP - 263

EP - 271

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -